CN Patent

CN109293674A — Gdc-0032的多晶型物、其制备方法和药物用途

Assigned to F Hoffmann La Roche AG · Expires 2019-02-01 · 7y expired

What this patent protects

本发明涉及(2‑(4‑(2‑(1‑异丙基‑3‑甲基‑1H‑1,2,4‑三唑‑5‑基)‑5,6‑二氢苯并[f]咪唑并[1,2‑d][1,4]氧氮杂 ‑9‑基)‑1H‑吡唑‑1‑基)‑2‑甲基丙酰胺(GDC‑0032,塔西利昔)的结晶性多晶型物、其使用方法及制备方法。

USPTO Abstract

本发明涉及(2‑(4‑(2‑(1‑异丙基‑3‑甲基‑1H‑1,2,4‑三唑‑5‑基)‑5,6‑二氢苯并[f]咪唑并[1,2‑d][1,4]氧氮杂 ‑9‑基)‑1H‑吡唑‑1‑基)‑2‑甲基丙酰胺(GDC‑0032,塔西利昔)的结晶性多晶型物、其使用方法及制备方法。

Drugs covered by this patent

Patent Metadata

Patent number
CN109293674A
Jurisdiction
CN
Classification
—
Expires
2019-02-01
Drug substance claim
No
Drug product claim
No
Assignee
F Hoffmann La Roche AG
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.